Online inquiry

IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13110MR)

This product GTTS-WQ13110MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ACVRL1 gene. The antibody can be applied in Hepatocellular carcinoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000020.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 94
UniProt ID P37023
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ13110MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3979MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ14545MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SAR156597
GTTS-WQ13326MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-06741086
GTTS-WQ8084MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ14066MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3918
GTTS-WQ8338MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HN-66000
GTTS-WQ8062MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ3809MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BB-10901
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW